Literature DB >> 20808139

The relationship of cardiovascular risk factors to Alzheimer disease in Choctaw Indians.

Myron F Weiner1, Linda S Hynan, Heidi Rossetti, Kyle B Womack, Roger N Rosenberg, Yun-Hua Gong, Bao-Xi Qu.   

Abstract

OBJECTIVES: To test the hypothesis that cardiovascular risk factors (CRFs) influence predisposition to and the clinical course of Alzheimer disease (AD), the authors compared Choctaw Indians, a group with known high CRF with white persons with AD. In addition to CRF history, the authors investigated the frequency of apolipoprotein E4 (apoE4) genotype andplasma homocysteine (HC) levels.
METHOD: The authors compared 39 Choctaw Indians with AD and 39 Choctaw Indians without AD to 39 white persons with AD with all groups similar in age. CRF history included diabetes, hypertension, high cholesterol or hypolipidemic agent use, or myocardial infarction. The authors also compared plasma HC concentration and apoE4 allele frequency.
RESULTS: Choctaw persons with AD differed significantly from white persons with AD in history of hypertension, diabetes, and in HC values but not from Indians without AD. There was a significantly lower apoE4 allele frequency in Choctaw Indian AD than white persons with AD, and both AD groups had an affected first degree relative significantly more often than Indian controls. There was no relationship between the number of CRF and age at onset among Indians or whites, whereas HC concentration was associated with significantly earlier age of onset for Choctaw Indians but not for whites.
CONCLUSIONS: This small study suggests that in Choctaw Indians modifiable risk factors may play more of a role in disease pathogenesis than in whites and that nonmodifiable risk factors such as apoE4 may play less of a role.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20808139      PMCID: PMC4603831          DOI: 10.1097/JGP.0b013e3181e89a46

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  33 in total

1.  Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer's disease.

Authors:  M F Weiner; G Vega; R C Risser; L S Honig; C M Cullum; D Crumpacker; R N Rosenberg
Journal:  Biol Psychiatry       Date:  1999-03-01       Impact factor: 13.382

2.  APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians.

Authors:  Oye Gureje; Adesola Ogunniyi; Olusegun Baiyewu; Brandon Price; Frederick W Unverzagt; Rebecca M Evans; Valerie Smith-Gamble; Kathleen A Lane; Sujuan Gao; Kathleen S Hall; Hugh C Hendrie; Jill R Murrell
Journal:  Ann Neurol       Date:  2006-01       Impact factor: 10.422

3.  Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease.

Authors:  I L Notkola; R Sulkava; J Pekkanen; T Erkinjuntti; C Ehnholm; P Kivinen; J Tuomilehto; A Nissinen
Journal:  Neuroepidemiology       Date:  1998       Impact factor: 3.282

4.  Vascular disease and risk factors, rate of progression, and survival in Alzheimer's disease.

Authors:  Deepika Bhargava; Myron F Weiner; Linda S Hynan; Ramon Diaz-Arrastia; Anne M Lipton
Journal:  J Geriatr Psychiatry Neurol       Date:  2006-06       Impact factor: 2.680

5.  Hypertension treatment patterns in American Indians: the strong heart study.

Authors:  J A Hayslett; J E Eichner; J L Yeh; W Wang; J Henderson; R B Devereux; T K Welty; R R Fabsitz; B V Howard; E T Lee
Journal:  Am J Hypertens       Date:  2001-09       Impact factor: 2.689

6.  Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study.

Authors:  Peter P Zandi; D Larry Sparks; Ara S Khachaturian; Joann Tschanz; Maria Norton; Martin Steinberg; Kathleen A Welsh-Bohmer; John C S Breitner
Journal:  Arch Gen Psychiatry       Date:  2005-02

7.  High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.

Authors:  Paul S Aisen; Lon S Schneider; Mary Sano; Ramon Diaz-Arrastia; Christopher H van Dyck; Myron F Weiner; Teodoro Bottiglieri; Shelia Jin; Karen T Stokes; Ronald G Thomas; Leon J Thal
Journal:  JAMA       Date:  2008-10-15       Impact factor: 56.272

Review 8.  Homocysteine and depression in later life.

Authors:  Osvaldo P Almeida; Kieran McCaul; Graeme J Hankey; Paul Norman; Konrad Jamrozik; Leon Flicker
Journal:  Arch Gen Psychiatry       Date:  2008-11

9.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.

Authors:  J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark
Journal:  Neurology       Date:  1989-09       Impact factor: 9.910

10.  Genetic associations with human longevity at the APOE and ACE loci.

Authors:  F Schächter; L Faure-Delanef; F Guénot; H Rouger; P Froguel; L Lesueur-Ginot; D Cohen
Journal:  Nat Genet       Date:  1994-01       Impact factor: 38.330

View more
  2 in total

1.  Total Brain and Hippocampal Volumes and Cognition in Older American Indians: The Strong Heart Study.

Authors:  Brenna Cholerton; Adam Omidpanah; Tara M Madhyastha; Thomas J Grabowski; Astrid M Suchy-Dicey; Dean K Shibata; Lonnie A Nelson; Steven P Verney; Barbara V Howard; William T Longstreth; Thomas J Montine; Dedra Buchwald
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Apr-Jun       Impact factor: 2.703

2.  Genetic Risk Factors for Alzheimer's Disease in Racial/Ethnic Minority Populations in the U.S.: A Scoping Review.

Authors:  Lindsey Rubin; Lucy A Ingram; Nicholas V Resciniti; Brianna Ashford-Carroll; Katherine Henrietta Leith; Aubrey Rose; Stephanie Ureña; Quentin McCollum; Daniela B Friedman
Journal:  Front Public Health       Date:  2021-12-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.